COGT PE Ratio & Valuation,Is COGT Overvalued

COGT Relative Valuation

COGT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, COGT is overvalued; if below, it's undervalued.

Historical Valuation

Cogent Biosciences Inc (COGT) is now in the Fair zone, suggesting that its current forward PS ratio of 886.56 is considered Fairly compared with the five-year average of -4.93. The fair price of Cogent Biosciences Inc (COGT) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：36.27

Fair

-17.41

-17.68

EV/EBITDA

Cogent Biosciences Inc. (COGT) has a current EV/EBITDA of -17.68. The 5-year average EV/EBITDA is -2.35. The thresholds are as follows: Strongly Undervalued below -9.83, Undervalued between -9.83 and -6.09, Fairly Valued between 1.38 and -6.09, Overvalued between 1.38 and 5.12, and Strongly Overvalued above 5.12. The current Forward EV/EBITDA of -17.68 falls within the Strongly Undervalued range.

-14.96

EV/EBIT

Cogent Biosciences Inc. (COGT) has a current EV/EBIT of -14.96. The 5-year average EV/EBIT is -3.43. The thresholds are as follows: Strongly Undervalued below -8.65, Undervalued between -8.65 and -6.04, Fairly Valued between -0.82 and -6.04, Overvalued between -0.82 and 1.79, and Strongly Overvalued above 1.79. The current Forward EV/EBIT of -14.96 falls within the Strongly Undervalued range.

886.56

Cogent Biosciences Inc. (COGT) has a current PS of 886.56. The 5-year average PS is 32685.52. The thresholds are as follows: Strongly Undervalued below -354799.02, Undervalued between -354799.02 and -161056.75, Fairly Valued between 226427.80 and -161056.75, Overvalued between 226427.80 and 420170.07, and Strongly Overvalued above 420170.07. The current Forward PS of 886.56 falls within the Historic Trend Line -Fairly Valued range.

-18.12

P/OCF

Cogent Biosciences Inc. (COGT) has a current P/OCF of -18.12. The 5-year average P/OCF is -5.71. The thresholds are as follows: Strongly Undervalued below -11.96, Undervalued between -11.96 and -8.84, Fairly Valued between -2.59 and -8.84, Overvalued between -2.59 and 0.54, and Strongly Overvalued above 0.54. The current Forward P/OCF of -18.12 falls within the Strongly Undervalued range.

-22.35

P/FCF

Cogent Biosciences Inc. (COGT) has a current P/FCF of -22.35. The 5-year average P/FCF is -6.35. The thresholds are as follows: Strongly Undervalued below -17.86, Undervalued between -17.86 and -12.10, Fairly Valued between -0.60 and -12.10, Overvalued between -0.60 and 5.15, and Strongly Overvalued above 5.15. The current Forward P/FCF of -22.35 falls within the Strongly Undervalued range.

Cogent Biosciences Inc (COGT) has a current Price-to-Book (P/B) ratio of 24.98. Compared to its 3-year average P/B ratio of 7.50 , the current P/B ratio is approximately 233.00% higher. Relative to its 5-year average P/B ratio of 5.64, the current P/B ratio is about 342.91% higher. Cogent Biosciences Inc (COGT) has a Forward Free Cash Flow (FCF) yield of approximately -4.67%. Compared to its 3-year average FCF yield of -19.45%, the current FCF yield is approximately -76.00% lower. Relative to its 5-year average FCF yield of -17.93% , the current FCF yield is about -73.97% lower.

24.98

P/B

Median3y

7.50

Median5y

5.64

-4.67

FCF Yield

Median3y

-19.45

Median5y

-17.93

Competitors Valuation Multiple

The average P/S ratio for COGT's competitors is 225.08, providing a benchmark for relative valuation. Cogent Biosciences Inc Corp (COGT) exhibits a P/S ratio of 886.56, which is 293.89% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of COGT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of COGT in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Cogent Biosciences Inc (COGT) currently overvalued or undervalued?

What is Cogent Biosciences Inc (COGT) fair value?

COGT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cogent Biosciences Inc (COGT) is between to according to relative valuation methord.

How does COGT's valuation metrics compare to the industry average?

What is the current P/B ratio for Cogent Biosciences Inc (COGT) as of Jan 08 2026?

As of Jan 08 2026, Cogent Biosciences Inc (COGT) has a P/B ratio of 24.98. This indicates that the market values COGT at 24.98 times its book value.

What is the current FCF Yield for Cogent Biosciences Inc (COGT) as of Jan 08 2026?

As of Jan 08 2026, Cogent Biosciences Inc (COGT) has a FCF Yield of -4.67%. This means that for every dollar of Cogent Biosciences Inc’s market capitalization, the company generates -4.67 cents in free cash flow.

What is the current Forward P/E ratio for Cogent Biosciences Inc (COGT) as of Jan 08 2026?

As of Jan 08 2026, Cogent Biosciences Inc (COGT) has a Forward P/E ratio of -17.41. This means the market is willing to pay $-17.41 for every dollar of Cogent Biosciences Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cogent Biosciences Inc (COGT) as of Jan 08 2026?

As of Jan 08 2026, Cogent Biosciences Inc (COGT) has a Forward P/S ratio of 886.56. This means the market is valuing COGT at $886.56 for every dollar of expected revenue over the next 12 months.

COGT Valuation